Sibylle Béchet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sibylle Béchet has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aline Sayd Gaban
Trinity College Institute of Neuroscience, Trinity College Dublin, D02 DK07 Dublin, Ireland
1 shared publication - Aífe Walsh
Trinity College Institute of Neuroscience, Trinity College Dublin, D02 DK07 Dublin, Ireland
1 shared publication - Eoin O'NEill
Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences & Trinity College Institute of Neuroscience, Trinity College, Dublin 2, Ireland
1 shared publication - Esther Ademola
Luxembourg Institute of Health (LIH), Transversal Translational Medicine, Strassen, Luxembourg
1 shared publication Fiona Hill
Department of Speech and Language Therapy, Tallaght Hospital, Dublin 22, Ireland
1 shared publication- Joëlle V. Fritz
Transversal Translational Medicine, Luxembourg Institute of Health, Luxembourg
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (2) , 265-277
Precision prevention for neurodegenerative diseases: lessons learnt from Alzheimer’s disease translated into perspectives for Parkinson’s disease
Population ageing is posing significant challenges for healthcare systems and societies worldwide. Neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, are among the leading contributors to disability, dependence, and healthcare costs in ageing societies. Prevention offers the most sustainable approach to reducing the burden of neurodegenerative diseases. While Alzheimer’s disease prevention is already advancing through biomarker-based early detection, identification of modifiable risk factors, and multi-domain interventions, efforts are now turning towards Parkinson’s disease, the fastest growing neurodegenerative disorder. Using deeply phenotyped cohorts of patients with Parkinson’s disease and people with prodromal stages of neurodegenerative diseases, novel biomarkers have enabled biological classification for improved diagnosis of Parkinson’s disease, including early cognitive impairments. The expanding knowledge of Parkinson’s disease risk factors is now being translated into primary and secondary prevention concepts within integrated care settings to effectively address the burden of neurodegenerative diseases for the people affected. Integrating biomarker-based risk stratification with scalable life-style based programmes offers a realistic pathway toward precision prevention in Parkinson’s disease.
- 26 December 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 133 (2) , 265-277
Open AccessPrecision prevention for neurodegenerative diseases: lessons learnt from Alzheimer’s disease translated into perspectives for Parkinson’s disease
Population ageing is posing significant challenges for healthcare systems and societies worldwide. Neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, are among the leading contributors to disability, dependence, and healthcare costs in ageing societies. Prevention offers the most sustainable approach to reducing the burden of neurodegenerative diseases. While Alzheimer’s disease prevention is already advancing through biomarker-based early detection, identification of modifiable risk factors, and multi-domain interventions, efforts are now turning towards Parkinson’s disease, the fastest growing neurodegenerative disorder. Using deeply phenotyped cohorts of patients with Parkinson’s disease and people with prodromal stages of neurodegenerative diseases, novel biomarkers have enabled biological classification for improved diagnosis of Parkinson’s disease, including early cognitive impairments. The expanding knowledge of Parkinson’s disease risk factors is now being translated into primary and secondary prevention concepts within integrated care settings to effectively address the burden of neurodegenerative diseases for the people affected. Integrating biomarker-based risk stratification with scalable life-style based programmes offers a realistic pathway toward precision prevention in Parkinson’s disease.
- Open Access
- 6 March 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (3) , 594
The Effects of the S1P Receptor Agonist Fingolimod (FTY720) on Central and Peripheral Myelin in Twitcher Mice
Krabbe’s disease (KD) is caused by mutations in the lysosomal enzyme galactocerebrosidase and is associated with psychosine toxicity. The sphingosine 1-phosphate receptor (S1PR) agonist fingolimod (FTY720) attenuates psychosine-induced cell death of human astrocytes, demyelination in cerebellar slices, as well as demyelination in the central nervous system of twitcher mice. Psychosine also accumulates in the peripheral nervous system in twitcher mice; however, effects of fingolimod on this peripheral myelin have not been examined. The aim of this study was to investigate the effects of fingolimod administration on peripheral and central markers of myelination. Here, we report that fingolimod administration (1 mg/kg/day) from postnatal day 5 (PND) onwards did not alter peripheral demyelination in the sciatic nerve of twitcher mice, despite significantly reducing myelin debris, glial reactivity, and neuronal damage in the cerebellum. We also find fingolimod administration improves twitching and mobility scores in twitcher mice. Importantly, we find that fingolimod significantly increases the lifespan of twitcher mice by approximately 5 days. These findings suggest differential effects of fingolimod on peripheral and central neuropathy in twitcher mice, which may explain its modest efficacy on behavior and lifespan.
- 6 March 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (3) , 594
Open AccessThe Effects of the S1P Receptor Agonist Fingolimod (FTY720) on Central and Peripheral Myelin in Twitcher Mice
Krabbe’s disease (KD) is caused by mutations in the lysosomal enzyme galactocerebrosidase and is associated with psychosine toxicity. The sphingosine 1-phosphate receptor (S1PR) agonist fingolimod (FTY720) attenuates psychosine-induced cell death of human astrocytes, demyelination in cerebellar slices, as well as demyelination in the central nervous system of twitcher mice. Psychosine also accumulates in the peripheral nervous system in twitcher mice; however, effects of fingolimod on this peripheral myelin have not been examined. The aim of this study was to investigate the effects of fingolimod administration on peripheral and central markers of myelination. Here, we report that fingolimod administration (1 mg/kg/day) from postnatal day 5 (PND) onwards did not alter peripheral demyelination in the sciatic nerve of twitcher mice, despite significantly reducing myelin debris, glial reactivity, and neuronal damage in the cerebellum. We also find fingolimod administration improves twitching and mobility scores in twitcher mice. Importantly, we find that fingolimod significantly increases the lifespan of twitcher mice by approximately 5 days. These findings suggest differential effects of fingolimod on peripheral and central neuropathy in twitcher mice, which may explain its modest efficacy on behavior and lifespan.
- Open Access
The Modulatory Effects of DMF on Microglia in Aged Mice Are Sex-Specific
There is a striking sex-related difference in the prevalence of many neurodegenerative diseases, highlighting the need to consider whether treatments may exert sex-specific effects. A change in microglial activation state is a common feature of several neurodegenerative diseases and is considered to be a key factor in driving the inflammation that characterizes these conditions. Among the changes that have been described is a switch in microglial metabolism towards glycolysis which is associated with production of inflammatory mediators and reduced function. Marked sex-related differences in microglial number, phenotype and function have been described in late embryonic and early postnatal life in rodents and some reports suggest that sexual dimorphism extends into adulthood and age and, in models of Alzheimer’s disease, the changes are more profound in microglia from female, compared with male, mice. Dimethyl fumarate (DMF) is a fumaric acid ester used in the treatment of psoriasis and relapsing remitting multiple sclerosis and, while its mechanism of action is unclear, it possesses anti-inflammatory and anti-oxidant properties and also impacts on cell metabolism. Here we treated 16–18-month-old female and male mice with DMF for 1 month and assessed its effect on microglia. The evidence indicates that it exerted sex-specific effects on microglial morphology and metabolism, reducing glycolysis only in microglia from female mice. The data suggest that this may result from its ability to inactivate glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Open AccessThe Modulatory Effects of DMF on Microglia in Aged Mice Are Sex-Specific
There is a striking sex-related difference in the prevalence of many neurodegenerative diseases, highlighting the need to consider whether treatments may exert sex-specific effects. A change in microglial activation state is a common feature of several neurodegenerative diseases and is considered to be a key factor in driving the inflammation that characterizes these conditions. Among the changes that have been described is a switch in microglial metabolism towards glycolysis which is associated with production of inflammatory mediators and reduced function. Marked sex-related differences in microglial number, phenotype and function have been described in late embryonic and early postnatal life in rodents and some reports suggest that sexual dimorphism extends into adulthood and age and, in models of Alzheimer’s disease, the changes are more profound in microglia from female, compared with male, mice. Dimethyl fumarate (DMF) is a fumaric acid ester used in the treatment of psoriasis and relapsing remitting multiple sclerosis and, while its mechanism of action is unclear, it possesses anti-inflammatory and anti-oxidant properties and also impacts on cell metabolism. Here we treated 16–18-month-old female and male mice with DMF for 1 month and assessed its effect on microglia. The evidence indicates that it exerted sex-specific effects on microglial morphology and metabolism, reducing glycolysis only in microglia from female mice. The data suggest that this may result from its ability to inactivate glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
- 16 August 2016
- Published by Springer Nature in Dysphagia
- Vol. 31 (6) , 721-729
Diagnostic Accuracy of the Modified Evan’s Blue Dye Test in Detecting Aspiration in Patients with Tracheostomy: A Systematic Review of the Evidence
Oropharyngeal aspiration (OPA) is a common occurrence in patients with tracheostomy. The modified Evan’s blue dye test (MEBDT) is an easily administered bedside procedure for the assessment of tracheostomised patients. However, studies evaluating the diagnostic accuracy of the MEBDT reach conflicting results. Therefore, we conducted a systematic review to determine the overall accuracy of the MEBDT in detecting OPA in adults with tracheostomy. The search strategy incorporated searching electronic databases, checking reference lists and citations and retrieving unpublished data. Data of primary studies were extracted and examined by three independent reviewers. The assessment of the methodological quality of included studies was performed using the QUADAS-2 tool. Six studies met the inclusion criteria for this systematic review. The studies presented significant disparities in study design and patient characteristics. Furthermore, high discrepancies in the administration of MEBDT across studies were noted. Therefore, a meta-analysis was not considered appropriate. Sensitivity estimates varied widely across the studies (38–95 %), indicating that the MEBDT is unreliable in detecting OPA. However, the studies emerge with overall high specificity values, ranging from 79 to 100 %. This true negative rate suggests that the MEBDT correctly identifies patients without OPA. This review highlights the need for further research studies assessing the accuracy of the MEBDT in detecting aspiration in patients with tracheostomy, using a standardised and reliable procedure. Outcomes from such studies will update the current level of evidence in relation to the MEBDT and consequently define best clinical practice.
- 16 August 2016
- Published by Springer Nature in Dysphagia
- Vol. 31 (6) , 721-729
Diagnostic Accuracy of the Modified Evan’s Blue Dye Test in Detecting Aspiration in Patients with Tracheostomy: A Systematic Review of the Evidence
Oropharyngeal aspiration (OPA) is a common occurrence in patients with tracheostomy. The modified Evan’s blue dye test (MEBDT) is an easily administered bedside procedure for the assessment of tracheostomised patients. However, studies evaluating the diagnostic accuracy of the MEBDT reach conflicting results. Therefore, we conducted a systematic review to determine the overall accuracy of the MEBDT in detecting OPA in adults with tracheostomy. The search strategy incorporated searching electronic databases, checking reference lists and citations and retrieving unpublished data. Data of primary studies were extracted and examined by three independent reviewers. The assessment of the methodological quality of included studies was performed using the QUADAS-2 tool. Six studies met the inclusion criteria for this systematic review. The studies presented significant disparities in study design and patient characteristics. Furthermore, high discrepancies in the administration of MEBDT across studies were noted. Therefore, a meta-analysis was not considered appropriate. Sensitivity estimates varied widely across the studies (38–95 %), indicating that the MEBDT is unreliable in detecting OPA. However, the studies emerge with overall high specificity values, ranging from 79 to 100 %. This true negative rate suggests that the MEBDT correctly identifies patients without OPA. This review highlights the need for further research studies assessing the accuracy of the MEBDT in detecting aspiration in patients with tracheostomy, using a standardised and reliable procedure. Outcomes from such studies will update the current level of evidence in relation to the MEBDT and consequently define best clinical practice.